Cost components | Mean costs | SD1 | Minimum | Median | Maximum | 95% CI | % of total direct costs | Estimated annual direct costs2 |
---|---|---|---|---|---|---|---|---|
Total direct costs | 4949 | 6079 | 0 | 2062 | 29,231 | 4088; 5863 | 100 | 19,796 |
 Medication (n = 168) | 2658 | 4557 | 0 | 321 | 21,546 | 2060; 3297 | 53.7 | 10,632 |
  mTOR inhibitors* (n = 49) | 2309 | 4435 | 0 | 0 | 20,054 | 1715; 2928 | 46.6 | 9236 |
  Antiseizure drugs (n = 154) | 260 | 378 | 0 | 159 | 3027 | 213; 312 | 5.3 | 1040 |
  Other prescription drugs (n = 62) | 72 | 352 | 0 | 0 | 3569 | 33; 122 | 1.5 | 288 |
  OTC drugs and supplements (n = 30) | 11 | 44 | 0 | 0 | 349 | 6; 17 | 0.2 | 44 |
  Emergency medication (n = 23) | 5 | 24 | 0 | 0 | 266 | 2; 9 | 0.1 | 20 |
 Hospitalization (n = 41) | 1027 | 3467 | 0 | 0 | 26,802 | 579; 1503 | 20.8 | 4108 |
 Ancillary therapies (n = 116) | 407 | 470 | 0 | 212 | 1951 | 345; 472 | 8.2 | 1628 |
 Outpatient treatment (n = 169) | 346 | 357 | 0 | 255 | 2250 | 298; 396 | 7.0 | 1384 |
 Diagnostics (n = 153) | 156 | 194 | 0 | 101 | 1370 | 130; 186 | 3.2 | 624 |
 Auxillary material (n = 19) | 138 | 738 | 0 | 0 | 8130 | 52; 241 | 2.8 | 552 |
 Rehabilitation (n = 2) | 27 | 287 | 0 | 0 | 3671 | 0; 67 | 0.6 | 108 |
 Emergency service use (n = 5) | 23 | 145 | 0 | 0 | 1200 | 7; 46 | 0.5 | 92 |
 Specific diets (n = 11) | 22 | 122 | 0 | 0 | 1100 | 8; 41 | 0.4 | 88 |
 Transport costs (n = 51) | 9 | 34 | 0 | 0 | 374 | 5; 14 | 0.2 | 36 |
 Co-payments for therapies (n = 64) | 125 | 297 | 0 | 0 | 2020 | 87; 167 | 2.5 | 500 |
 Other co-payments (n = 22) | 15 | 54 | 0 | 0 | 400 | 8; 23 | 0.3 | 60 |